18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial - The Lancet

Por um escritor misterioso
Last updated 10 novembro 2024
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
PDF) Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial, BMC Cancer
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
Radiotherapy in Prostate Cancer: Utilization of Adjuvant and Salvage Radiotherapy
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
Differences in Failure-Free Survival After Salvage Radiotherapy Guided by Conventional Imaging Versus 18F-Fluciclovine PET/CT in Postprostatectomy Patients: A Post Hoc Substratification Analysis of the EMPIRE-1 Trial
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
Clinical practice in prostate PET imaging - Sean J. Huls, Brian Burkett, Eric Ehman, Val J. Lowe, Rathan M. Subramaniam, A. Tuba Kendi, 2023
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on 18F-Fluciclovine PET/CT Guidance
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
Prostate Cancer Diagnostics Novel Approaches Are Leaving Conventional Imaging Behind - The ASCO Post
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
Randomized Trial of Conventional Versus Conventional Plus Fluciclovine (18F) Positron Emission Tomography/Computed Tomography–Guided Postprostatectomy Radiation Therapy for Prostate Cancer: Volumetric and Patient-Reported Analyses of Toxic
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
Mask R-CNN assisted 2.5D object detection pipeline of 68Ga-PSMA-11 PET/CT-positive metastatic pelvic lymph node after radical prostatectomy from solely CT imaging
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
Axumin LOCATE Trial Results Axumin® (fluciclovine F 18) Injection
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
Mask R-CNN assisted 2.5D object detection pipeline of 68Ga-PSMA-11 PET/CT-positive metastatic pelvic lymph node after radical prostatectomy from solely CT imaging

© 2014-2024 lexenimomnia.com. All rights reserved.